West Pharmaceutical (NYSE: WST) VP sells 896 shares after option exercise

Rhea-AI Filing Summary

West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters exercised stock options for 896 shares of common stock at $173.22 per share and on the same day sold 896 shares in an open-market sale at a weighted average price of $300.6688. After these transactions, he directly holds 1,522.81 shares.

Insider Trade Summary

Net Seller: 896 shares ($269,399)

Net Sell 3 txns

Insider Winters Chad

Role VP, Chief Accounting Officer

Sold 896 shs ($269K)

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	896	$0.00	--
Exercise	Common Stock	896	$173.22	$155K
Sale	Common Stock	896	$300.6688	$269K

Holdings After Transaction: Stock Options (Right to Buy) — 0 shares (Direct, null); Common Stock — 2,418.81 shares (Direct, null)

Footnotes (1)

1. The price reported in column 4 is a weighted average price. This award granted on February 18, 2020 vested in four equal annual installments beginning on February 18, 2021.

Key Figures

Shares sold: 896 shares Sale price: $300.6688 per share Options exercised: 896 shares +4 more

7 metrics

Shares sold 896 shares Common stock open-market sale on April 27, 2026

Sale price $300.6688 per share Weighted average sale price for 896 common shares

Options exercised 896 shares Stock option exercise into common stock on April 27, 2026

Exercise price $173.22 per share Conversion or exercise price of stock options granted February 18, 2020

Shares held after sale 1,522.81 shares Direct common stock holdings following the sale transaction

Shares after exercise 2,418.81 shares Direct common stock holdings immediately after option exercise, before sale

Option expiration February 18, 2030 Expiration date of the exercised stock option award

Key Terms

open-market sale, Stock Options (Right to Buy), derivative security, weighted average price, +1 more

5 terms

open-market sale financial

"transaction_action: "open-market sale" for 896 common shares"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Options (Right to Buy) financial

"security_title: "Stock Options (Right to Buy)" in derivative transaction"

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

weighted average price financial

"footnote: "The price reported in column 4 is a weighted average price.""

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vested in four equal annual installments financial

"footnote: "vested in four equal annual installments beginning on February 18, 2021.""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winters Chad

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PENNSYLVANIA 19341

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/27/2026		M		896	A	$173.22	2,418.81	D
Common Stock	04/27/2026		S		896	D	$300.6688(1)	1,522.81	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$173.22	04/27/2026		M			896	02/18/2021(2)	02/18/2030	Common Stock	896	$0	0	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price.

2. This award granted on February 18, 2020 vested in four equal annual installments beginning on February 18, 2021.

	/s/ Louis Lalli, as an agent for Chad Winters	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did WST executive Chad Winters report on this Form 4?

Chad Winters, VP and Chief Accounting Officer of West Pharmaceutical Services, reported exercising stock options for 896 common shares and selling 896 common shares in an open-market transaction, both dated April 27, 2026, according to the Form 4 insider filing data provided.

At what prices did Chad Winters of WST exercise options and sell shares?

Chad Winters exercised stock options at $173.22 per share for 896 West Pharmaceutical common shares and sold 896 common shares at a weighted average price of $300.6688 per share, reflecting the reported open-market transaction on April 27, 2026 in the Form 4 data.

How many WST shares does Chad Winters hold after the reported transactions?

After exercising options for 896 shares and selling 896 shares, Chad Winters directly holds 1,522.81 shares of West Pharmaceutical common stock, based on the total_shares_following_transaction figures disclosed for the non-derivative common stock transactions in the Form 4 insider filing data.

What stock option award did Chad Winters exercise in this WST Form 4 filing?

The exercised award was a stock option for 896 West Pharmaceutical common shares, with a conversion or exercise price of $173.22 per share, originally granted on February 18, 2020 and vesting in four equal annual installments beginning February 18, 2021, as stated in the footnote.

Did Chad Winters retain any derivative options after these WST transactions?

The Form 4 data show a derivative transaction for stock options covering 896 shares, with the derivative position reported as zero shares following the exercise, and the derivativeSummary field is empty, indicating no remaining reported derivative options from this specific award after the April 27, 2026 exercise.